Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.18B 11.31B 10.43B 19.65B 1,339B 20B 134B 52.42B 665B 52.65B 51.5B 2,236B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.32B 10.52B 9.7B 18.27B 1,245B 18.6B 124B 48.75B 618B 48.96B 47.89B 2,079B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
02/04/25 Issuer saleCompany 10,000 0.0094%
02/04/25 Issuer sale

Director

55,511 0.0522%
02/04/25 Issuer sale

Chief Technology Officer

265,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+116.86% 14.02B
+6.17%+13.26%+33.13%-1.04% 75.12B
+5.21%-7.36%+19.66%+183.04% 47.63B
+3.25%+52.70%+52.70%+52.70% 49.48B
-3.81%+6.32%-54.61%-54.17% 42.95B
-0.62%+3.64%+64.19%-21.60% 30.72B
-3.23%+5.40%+58.59%+94.94% 24.93B
+6.29%+1.58%+80.16%-51.19% 22.98B
-1.59%-3.61%-11.53%+150.58% 19.56B
+1.06%+4.46%+77.23%+131.94% 17.19B
Average +0.48%+2.79%+31.95%+60.21% 34.46B
Weighted average by Cap. +1.61%+3.83%+29.21%+47.30%

Financials

2023 2024
Net sales 464M 403M 375M 345M 651M 44.33B 662M 4.43B 1.74B 22.02B 1.74B 1.71B 74.04B 681M 591M 549M 506M 954M 65B 971M 6.5B 2.55B 32.28B 2.56B 2.5B 109B
Net income -140M -121M -113M -104M -196M -13.33B -199M -1.33B -522M -6.62B -525M -513M -22.27B -74.68M -64.86M -60.23M -55.55M -105M -7.13B -107M -713M -279M -3.54B -280M -274M -11.91B
Net Debt -481M -418M -388M -358M -674M -45.92B -686M -4.59B -1.8B -22.81B -1.81B -1.77B -76.7B -984M -855M -794M -732M -1.38B -93.95B -1.4B -9.4B -3.68B -46.66B -3.7B -3.61B -157B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock